Peptonic Medical (publ) announced today that it is now introducing VagiVital®️ range of hormone free treatments to the US market.
VagiVital long term vision is to enable women to manage their intimate health with clinically proven and trusted self-care products. All from diagnosing, to treating and preventing intimate health conditions.
Therefor it is with great excitement that Peptonic today announces that the first of VagiVital products now enter the US market. VagiVital AktivGel for the treatment of vaginal dryness and VagiVital Moisturizing V Cleanser feature a complete regimen for daily vaginal health that will be available for all women in the USA.
– As women in US tend to be more concerned about vaginal hormone treatments compared to for example women in the Nordics, we are excited about the coming phase in the development of Peptonic internationally, says Erik Sundquist, CEO of Peptonic Medical.
Initially VagiVital products will be available through its own web shop https://us.vagivital.com/ and on Amazon from this week. This way Peptonic will learn the US VagiVital consumer persona, which is of essence for further expansion into additional partnerships and distribution channels on and offline.
– The buildup model is, with some local adoptions, similar to the one we have successfully used in Sweden and we are excited to now be under way in the US market, says Mikael Svensson, General Manager Peptonic US.
The expansion into US of the VagiVital range of products underscores Peptonics commitment to women’s health globally.
Erik Sundquist, CEO
Telefon: + 46 722 49 90 43
About Peptonic Medical AB
Peptonic Medical AB (publ) is an innovative medtech company that conducts research, development and sales of medical devices and lifestyle products in the field of women’s health. Peptonic launched its first product, VagiVital®️ Active Gel against vaginal atrophy, in July 2018. In April 2021, VagiVital®️ Moisturizing V Cleanser, was launched, a moisturizing and preventive intimate wash. The company was founded in 2009 and the share has been traded on Spotlight (www.spotlightstockmarket.com) in Stockholm since 2014.
Since August 2020, Lune Group Oy Ltd. has been a wholly owned subsidiary of Peptonic Medical. The company was founded in 2005 with the purpose to lead a light-hearted menstrual revolution in positive spirit via patented menstrual cups. The company is now evolving into leading the way in sustainable, intimate well-being.
In October 2021, all assets of Israeli company Common Sense Ltd were acquired. Common Sense has developed unique and patented self-tests to accurately diagnose bacterial vaginosis and amniotic fluid leakage respectively.